卖什么
A therapeutics platform for curing inflammatory disorders
商业模式拆解
买家：谁掌握预算？
未核实Pharma partners/acquirers and biotech investors (no product sold).
工作流：什么输入变成什么输出？
Uses patient-sample insights to develop medicines that restore immune regulation rather than suppress it, for Crohn's disease, ankylosing spondylitis and psoriasis.
经济账：省了什么，怎么收费？
未核实Drug-development company funded by investors; value from licensing/partnering or acquiring therapeutics. Claims only 25% of patients benefit long term from current therapies.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2021 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.